Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells $128,435.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the sale, the executive vice president directly owned 106,353 shares in the company, valued at approximately $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Jon Brown also recently made the following trade(s):

• On Friday, May 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $59.91, for a total transaction of $101,847.00.
• On Wednesday, April 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $63.04, for a total value of $107,168.00.

DexCom Price Performance

Shares of DexCom stock opened at $72.47 on Friday. The firm’s 50-day moving average price is $67.07 and its two-hundred day moving average price is $67.92. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The stock has a market capitalization of $27.96 billion, a price-to-earnings ratio of 30.97, a P/E/G ratio of 1.13 and a beta of 1.45. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.32 EPS. On average, equities analysts predict that DexCom, Inc. will post 2.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on DXCM. Mizuho set a $85.00 target price on shares of DexCom and gave the stock an “outperform” rating in a report on Tuesday, June 9th. Sanford C. Bernstein set a $77.00 target price on DexCom in a research report on Friday, May 1st. Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the stock a “buy” rating in a research report on Monday, May 18th. Raymond James Financial restated a “strong-buy” rating and issued a $91.00 price objective on shares of DexCom in a research note on Monday, June 8th. Finally, BTIG Research reissued a “buy” rating and issued a $85.00 price objective on shares of DexCom in a research report on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $84.83.

Hedge Funds Weigh In On DexCom

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Gradient Investments LLC grew its holdings in DexCom by 13.8% in the fourth quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock worth $22,035,000 after purchasing an additional 40,343 shares during the period. Nordea Investment Management AB increased its holdings in DexCom by 118.6% during the 4th quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock worth $16,988,000 after purchasing an additional 137,986 shares in the last quarter. NEOS Investment Management LLC grew its holdings in DexCom by 58.7% during the third quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock worth $11,842,000 after buying an additional 65,066 shares in the last quarter. Banco Santander S.A. grew its stake in shares of DexCom by 28.9% in the 3rd quarter. Banco Santander S.A. now owns 250,310 shares of the medical device company’s stock worth $16,843,000 after acquiring an additional 56,062 shares in the last quarter. Finally, Banque Pictet & Cie SA grew its position in DexCom by 58.2% in the 4th quarter. Banque Pictet & Cie SA now owns 109,823 shares of the medical device company’s stock worth $7,289,000 after purchasing an additional 40,411 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.